BNP Paribas Financial Markets Increases Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

BNP Paribas Financial Markets boosted its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 16.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,997 shares of the medical instruments supplier’s stock after acquiring an additional 991 shares during the quarter. BNP Paribas Financial Markets’ holdings in ICU Medical were worth $1,275,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Innealta Capital LLC purchased a new position in shares of ICU Medical during the second quarter valued at approximately $32,000. Hexagon Capital Partners LLC grew its position in ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares during the period. Allworth Financial LP raised its stake in ICU Medical by 100.0% during the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 100 shares during the last quarter. Venturi Wealth Management LLC raised its stake in ICU Medical by 1,510.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 302 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of ICU Medical during the 2nd quarter valued at $70,000. Institutional investors own 96.10% of the company’s stock.

ICU Medical Price Performance

ICUI opened at $161.31 on Tuesday. The business has a fifty day moving average of $172.37 and a 200 day moving average of $149.93. The stock has a market cap of $3.95 billion, a P/E ratio of -35.30 and a beta of 0.62. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 52-week low of $83.26 and a 52-week high of $196.26.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp upped their target price on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Raymond James increased their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Jefferies Financial Group began coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective for the company. Finally, StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $173.00.

Insiders Place Their Bets

In related news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $18,665,666.78. This represents a 10.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David C. Greenberg sold 972 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total value of $153,682.92. Following the sale, the director now owns 5,037 shares of the company’s stock, valued at approximately $796,400.07. This represents a 16.18 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,364 shares of company stock worth $6,869,878. 6.70% of the stock is currently owned by company insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.